IL1B and familial Mediterranean fever: Finally, the adoption of new therapies such as IL-1 inhibitors and anti-IL-6 may represent a useful tool, but larger clinical trials are required to confirm their efficacy in those patients non-responder or intolerant to colchicine, which still remains a cornerstone in FMF clinical management.